

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Daniel J. Smith *et al.*
SERIAL NUMBER : 10/797,821 EXAMINER : Rodney P. Swartz, Ph.D.
FILING DATE : March 9, 2004 ART UNIT : 1645
FOR : GLUCAN BINDING PROTEIN AND GLUCOSYLTRANSFERASE IMMUNOGENS

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

June 7, 2006
Boston, Massachusetts

06/12/2006 DTESSEM1 00000074 10797821

02 FC:2814

65.00 OP

TERMINAL DISCLAIMER

The owner, The Forsyth Institute, of 100 per cent interest in the instant application hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application, which would extend beyond the expiration date of the full statutory term of any patent granted on pending reference Application Number 10/383,930, filed March 7, 2003, as such term is defined in 35 U.S.C. §154 to 156 and 173, as the term of any patent granted on said reference application may be shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application. The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and any patent granted on the reference application are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 U.S.C. §154 to 156 and 173 of any patent granted on said reference application, as the term of any patent granted on said reference application may be

APPLICANTS: Smith and Taubman


SERIAL NUMBER: 10/797,821

shortened by any terminal disclaimer filed prior to the grant of any patent on the pending reference application, in the event that any such patent: granted on the pending reference application: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 C.F.R. §1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer filed prior to its grant.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

The undersigned Applicant's representatives file this Terminal Disclaimer under 37 C.F.R. § 1.34(a). A check (#22594) for \$65.00 for terminal disclaimer fee under 37 C.F.R. § 1.20(d) is included. The Commissioner is authorized to charge any additional fees or make any credits to the account of the undersigned, Deposit Account No. 50-0311, Ref. No. 25669-020.

Respectfully submitted,

 Ingrid A. Beattie, Reg. No. 42,306
Attorney for Applicants

c/o MINTZ LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel.: (617) 542 6000
Fax: (617) 542-2241
Customer No. 30623